Search results for "immunotherapy"

showing 10 items of 830 documents

T-cell receptor transfer into human T cells with ecotropic retroviral vectors

2014

Adoptive T-cell transfer for cancer immunotherapy requires genetic modification of T cells with recombinant T-cell receptors (TCRs). Amphotropic retroviral vectors (RVs) used for TCR transduction for this purpose are considered safe in principle. Despite this, TCR-coding and packaging vectors could theoretically recombine to produce replication competent vectors (RCVs), and transduced T-cell preparations must be proven free of RCV. To eliminate the need for RCV testing, we transduced human T cells with ecotropic RVs so potential RCV would be non-infectious for human cells. We show that transfection of synthetic messenger RNA encoding murine cationic amino-acid transporter 1 (mCAT-1), the re…

CD4-Positive T-LymphocytesAdoptive cell transfermedicine.medical_treatmentGenetic enhancementGenetic VectorsReceptors Antigen T-CellCD8-Positive T-LymphocytesBiologyImmunotherapy AdoptiveJurkat cellsVesicular stomatitis Indiana virusCell LineJurkat CellsMiceTransduction (genetics)Viral Envelope ProteinsCancer immunotherapyTransduction GeneticGeneticsmedicineAnimalsHumansRNA MessengerMolecular BiologyCationic Amino Acid Transporter 1Membrane GlycoproteinsHEK 293 cellsT-cell receptorTransfectionAdoptive TransferVirologyElectroporationHEK293 CellsRetroviridaeLeukemia Virus Gibbon ApeMolecular MedicinePlasmidsGene Therapy
researchProduct

Adoptive transfer of ex vivo expanded SARS‐CoV‐2‐specific cytotoxic lymphocytes: A viable strategy for COVID‐19 immunosuppressed patients?

2021

Cellular and humoral response to acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infections is on focus of research. We evaluate herein the feasibility of expanding virus‐specific T cells (VST) against SARS‐CoV‐2 ex vivo through a standard protocol proven effective for other viruses. The experiment was performed in three different donors' scenarios: (a) SARS‐CoV‐2 asymptomatic infection/negative serology, (b) SARS‐CoV‐2 symptomatic infection/positive serology, and (c) no history of SARS‐CoV‐2 infection/negative serology. We were able to obtain an expanded VST product from donors 1 and 2 (1.6x and 1.8x increase of baseline VST count, respectively) consisting in CD3 + cells (80.3% and 6…

CD4-Positive T-LymphocytesAdoptive cell transferviruses030230 surgerymedicine.disease_causevirus-specific T cellsAsymptomaticSARS‐CoV‐2Serology03 medical and health sciences0302 clinical medicineCOVID‐19medicineCytotoxic T cellHumansRespiratory systemthird‐party donorsCoronavirusTransplantationbusiness.industrySARS-CoV-2COVID-19Original Articlesvirus‐specific T cellsAdoptive Transferlymphocyte expansionrespiratory virusInfectious DiseasesImmunologyRespiratory virus030211 gastroenterology & hepatologyOriginal Articlethird-party donorsmedicine.symptombusinessadoptive immunotherapyEx vivo
researchProduct

In vitro generation of CD4+CD25+ regulatory cells from murine naive T cells

2007

CD4+ CD25+ regulatory T cells (Tregs) are crucial for the maintenance of immunological tolerance. Recent data indicate that Tregs not only develop in the thymus during ontogeny but can also differentiate from naive T cells in the periphery. The following protocol describes a method by which Tregs are generated in vitro by stimulation of naive T cells in the presence of transforming growth factor beta (Ti-Tregs). In vitro-induced regulatory T cells express markers of conventional Treg such as CD25 and the genetic program committing transcription factor FoxP3. Functionally the in vitro-generated Ti-Tregs suppress T-cell activation and proliferation while in vivo these cells have been proven t…

CD4-Positive T-LymphocytesCD3 ComplexT-Lymphocytesmedicine.medical_treatmentchemical and pharmacologic phenomenaBiologyBioinformaticsT-Lymphocytes RegulatoryGeneral Biochemistry Genetics and Molecular BiologyMiceInterleukin 21CD28 AntigensmedicineAnimalsCytotoxic T cellIL-2 receptorInterleukin 3Mice Inbred BALB CInterleukin-2 Receptor alpha SubunitFOXP3hemic and immune systemsTransfectionImmunotherapyTransforming growth factor betaCell biologyCD4 Antigensbiology.proteinBiomarkersNature Protocols
researchProduct

A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injec…

2001

Dendritic cells (DCs) elicit potent anti-tumoral T-cell responses in vitro and in vivo. However, different types of DC have yet to be compared for their capacity to induce anti-tumor responses in vivo at different developmental stages. Herein, we correlated the efficiencies of different types of monocyte-derived DC as vaccines on the resulting anti-tumor immune responses in vivo. Immature and mature DCs were separately pulsed with a peptide derived from tyrosinase, MelanA/MART-1 or MAGE-1 and a recall antigen. Both DC populations were injected every 2 weeks in different lymph nodes of the same patient. Immune responses were monitored before, during and after vaccination. Mature DCs induced …

CD4-Positive T-LymphocytesCancer Researchmedicine.medical_treatmentT cellchemical and pharmacologic phenomenaCD8-Positive T-LymphocytesInterferon-gammaImmune systemAdjuvants ImmunologicAntigenAntigens NeoplasmHumansMedicineCytotoxic T cellAntigen-presenting cellMelanomaNeoplasm Stagingbusiness.industryDendritic CellsImmunotherapyDendritic cellNeoplasm Proteinsmedicine.anatomical_structureOncologyImmunologyImmunizationLymph NodesPeptidesbusinessMelanoma-Specific AntigensCD8T-Lymphocytes CytotoxicInternational Journal of Cancer
researchProduct

CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib–associated renal carcinoma antigens with ubiquitous or…

2004

AbstractAllogeneic hematopoietic stem cell transplantation can induce considerable tumor remissions in metastatic renal-cell carcinoma (RCC) patients. The precise effector mechanisms mediating these graft-versus-tumor reactions are unknown. We studied RCC-directed CD8+ T-cell responses in blood lymphocytes of healthy individuals matched with established RCC cell lines for HLA-class I. In 21 of 22 allogeneic mixed lymphocyte/tumor-cell cultures (MLTCs), RCC-reactive cytotoxic T-lymphocytes (CTLs) were readily obtained. From MLTCs, 121 CD8+ CTL clones with memory phenotype were isolated. Their anti–RCC reactivity was restricted by multiple classical HLA-Ia molecules, in particular by HLA-A2, …

CD4-Positive T-LymphocytesCytotoxicity ImmunologicGenotypemedicine.medical_treatmentMolecular Sequence DataImmunologyCell SeparationHuman leukocyte antigenHematopoietic stem cell transplantationCross ReactionsBiologyurologic and male genital diseasesBiochemistryEpitheliumCell therapyEpitopesAntigenAntigens NeoplasmmedicineHumansTransplantation HomologousCytotoxic T cellAmino Acid SequenceCarcinoma Renal CellHistocompatibility Antigens Class ICell BiologyHematologyImmunotherapyFlow CytometryHematopoietic Stem CellsTissue DonorsCTL*HealthSpectrometry Mass Matrix-Assisted Laser Desorption-IonizationColonic NeoplasmsImmunologyMitogen-Activated Protein KinasesPeptidesCD8T-Lymphocytes CytotoxicBlood
researchProduct

Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines.

2006

AbstractIn HLA-incompatible hematopoietic stem cell transplantation, alloreactive donor T cells recognizing recipient mismatch HLA cause severe graft-versus-host disease (GVHD). Strategies allowing the selective depletion of alloreactive T cells as well as the enhancement of graft-versus-malignancy immunity would be beneficial. We generated donor CD8 T-cell lines in vitro using allogeneic recipient cells mismatched at a single HLA class I allele or haplotype as stimulators. Recipient cells were obtained from acute myeloid leukemias, renal-cell carcinomas, and CD40L-induced B lymphoblasts. Resulting alloreactive T cells were activated by incubating day 21 T-cell cultures with HLA-mismatch tr…

CD4-Positive T-LymphocytesHerpesvirus 4 HumanIsoantigensT cellImmunologyCD40 LigandCytomegalovirusGraft vs Host DiseaseHuman leukocyte antigenBiologyCD8-Positive T-LymphocytesIn Vitro TechniquesLymphocyte ActivationTransfectionBiochemistryImmunotherapy AdoptiveLymphocyte DepletionTumor Necrosis Factor Receptor Superfamily Member 9AntigenHLA AntigensT-Lymphocyte SubsetsmedicineCytotoxic T cellHumansCarcinoma Renal CellCells CulturedSkinB-LymphocytesImmunomagnetic SeparationLymphoblastCD137Cell BiologyHematologyT lymphocyteFibroblastsCytotoxicity Tests ImmunologicKidney Neoplasmsmedicine.anatomical_structureLeukemia MyeloidHistocompatibilityImmunologyK562 CellsCD8Blood
researchProduct

Prospective Study of the Evolution of Blood Lymphoid Immune Parameters during Dacarbazine Chemotherapy in Metastatic and Locally Advanced Melanoma Pa…

2014

BackgroundThe importance of immune responses in the control of melanoma growth is well known. However, the implication of these antitumor immune responses in the efficacy of dacarbazine, a cytotoxic drug classically used in the treatment of melanoma, remains poorly understood in humans.MethodsIn this prospective observational study, we performed an immunomonitoring of eleven metastatic or locally advanced patients treated with dacarbazine as a first line of treatment. We assessed by flow cytometry lymphoid populations and their activation state; we also isolated NK cells to perform in vitro cytotoxicity tests.ResultsWe found that chemotherapy induces lymphopenia and that a significantly hig…

CD4-Positive T-LymphocytesMaleSkin Neoplasmsmedicine.medical_treatmentCancer TreatmentGene ExpressionNK cellsLymphocyte ActivationT-Lymphocytes RegulatoryLeukocyte CountCellular typesMedicine and Health SciencesCytotoxic T cellProspective StudiesNeoplasm MetastasisProspective cohort studyImmune ResponseMelanomaAged 80 and overMultidisciplinarymedicine.diagnostic_testReverse Transcriptase Polymerase Chain ReactionMelanomaQRMiddle AgedFlow CytometryPrognosis3. Good healthDacarbazineKiller Cells NaturalTreatment OutcomeOncologyCutaneous MelanomaMedicineWhite blood cellsFemaleImmunotherapymedicine.drugResearch ArticleTumor ImmunologyAdultCell biologyBlood cellsCell SurvivalDacarbazineScienceImmune CellsImmunologyLocally advancedT cellsMalignant Skin NeoplasmsDermatologyCancer ImmunotherapyFlow cytometryImmune systemCell Line TumormedicineHumansAntineoplastic Agents AlkylatingAgedChemotherapyBiology and life sciencesbusiness.industrymedicine.diseaseAnimal cellsImmunologyCancer researchClinical ImmunologybusinessTranscription FactorsPLoS ONE
researchProduct

Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methot…

1999

SUMMARYImmunosuppressive therapy with methotrexate (MTX) has been established as effective treatment for patients with rheumatoid arthritis. To analyse the therapeutic potential and mechanisms of action of MTX, we determined serum cytokine levels and cytokine production by splenic T cells and macrophages in untreated and MTX-treated mice. Furthermore, we assessed the role of MTX in a murine model of experimental arthritis induced by collagen type II (CIA). MTX reduced spontaneous and IL-15-induced tumour necrosis factor (TNF) production by splenic T cells but not by macrophages from healthy mice in vitro in a dose-dependent manner. In contrast, interferon-gamma (IFN-γ) production was less s…

CD4-Positive T-LymphocytesMalemusculoskeletal diseasesT-Lymphocytesmedicine.medical_treatmentImmunologyArthritisMice TransgenicSpleenInterferon-gammaMiceImmune systemAnimalsImmunology and AllergyMedicineheterocyclic compoundsInterferon gammaskin and connective tissue diseasesInterleukin 4Interleukin-15Mice KnockoutMice Inbred BALB CInterleukin-6Tumor Necrosis Factor-alphabusiness.industryMacrophagesOriginal ArticlesImmunotherapymedicine.diseaseArthritis ExperimentalMethotrexatemedicine.anatomical_structureCytokineMice Inbred DBAImmunologyCytokinesTumor necrosis factor alphaCollagenInterleukin-4businessImmunosuppressive AgentsSpleenmedicine.drug
researchProduct

Antigen-Driven T-Cell Selection in Patients with Cervical Cancer as Evidenced by T-Cell Receptor Analysis and Recognition of Autologous Tumor

2002

ABSTRACTWe characterized the T-cell receptor (TCR) repertoire in freshly harvested tumor lesions, in short-term-expanded CD4+tumor infiltrating lymphocytes (TIL) as well as in CD4+and CD8+peripheral blood lymphocytes (PBL) from three patients with cervical cancer. Skewing of the T-cell repertoire as defined by measuring the length of the complementarity-determining region 3 (CDR3) of the TCR VA and VB chains was observed in CD8+PBL, in freshly harvested tumor tissue, as well as in CD4+TIL. Comparative analysis of the TCR repertoire revealed unique monoclonal TCR transcripts within the tumor lesion which were not present in PBL, suggesting selection of TCR clonotypes due to antigenic stimula…

CD4-Positive T-LymphocytesMicrobiology (medical)medicine.medical_treatmentClinical BiochemistryImmunologyReceptors Antigen T-CellUterine Cervical Neoplasmschemical and pharmacologic phenomenaCD8-Positive T-LymphocytesBiologyEpitopeEpitopesLymphocytes Tumor-InfiltratingImmune systemAntigenAntigens NeoplasmExperimental Clinical InvestigationmedicineHumansImmunology and AllergyTumor-infiltrating lymphocytesT-cell receptorhemic and immune systemsImmunotherapyComplementarity Determining RegionsImmunologyT cell selectionFemaleCD8Clinical and Vaccine Immunology
researchProduct

Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination.

1999

Myelin basic protein (MBP)-reactive T cells may play an important role in the autoimmune pathogenesis of multiple sclerosis (MS). MBP-reactive T cells can be specifically targeted by T cell vaccination, a procedure whereby MS patients are immunized with attenuated autologous MBP reactive T cells. T cell vaccination induces immune responses to the vaccine cells together with a depletion of MBP reactive T cells. Forty-nine MS patients were treated with T cell vaccination in an extended phase I trial to study the safety, immune responses and clinical effects of T cell vaccination. In the present paper the immune responses towards the vaccine cells were characterized. Substantial long-term in v…

CD4-Positive T-LymphocytesMultiple SclerosisT-LymphocytesImmunologyT-cell vaccinationLymphocyte ActivationInterleukin 21Immunology and AllergyMedicineCytotoxic T cellHumansIL-2 receptorAntigen-presenting cellImmunity CellularVaccinesCD40biologyClinical Trials Phase I as Topicbusiness.industryVaccinationMyelin Basic ProteinNatural killer T cellLymphocyte SubsetsVaccines InactivatedCTLA-4ImmunologyAntibody Formationbiology.proteinCytokinesImmunotherapybusinessJournal of autoimmunity
researchProduct